By Counterforce Health Team in Amondys 45 (casimersen) —

Coding That Helps Get Amondys 45 (casimersen) Covered by Cigna in Texas: ICD-10, HCPCS J-Code, and NDC Guide

Answer Box: Get Amondys 45 Covered by Cigna in Texas

Getting Amondys 45 (casimersen) covered by Cigna requires precise coding and documentation. Use ICD-10 code G71.01 for Duchenne muscular dystrophy, bill under HCPCS J1426 (1 unit = 10 mg), and include genetic testing confirming exon 45 mutation amenability. Submit through Cigna's medical benefit (not pharmacy) with complete dosing calculations: 30 mg/kg weekly IV. First step today: Verify your patient's genetic test results and calculate exact billing units before submitting the prior authorization through Cigna's provider portal.

Table of Contents

  1. Coding Basics: Medical vs. Pharmacy Benefit Paths
  2. ICD-10 Mapping for Duchenne Muscular Dystrophy
  3. Product Coding: HCPCS, NDC, and Units Math
  4. Clean Prior Authorization Request Anatomy
  5. Frequent Coding Pitfalls
  6. Verification with Cigna Resources
  7. Pre-Submission Audit Checklist
  8. Appeals Process in Texas
  9. FAQ

Coding Basics: Medical vs. Pharmacy Benefit Paths

Amondys 45 (casimersen) is always billed under the medical benefit, not the pharmacy benefit, because it requires IV administration by a healthcare provider. This buy-and-bill process means your clinic purchases the drug and submits claims to Cigna for reimbursement.

Medical Benefit Path:

  • Prior authorization through Cigna's medical review team
  • Billed using HCPCS J-codes on medical claims (CMS-1500 or 837P)
  • Administered in clinic, infusion center, or home health setting
  • Requires provider oversight and monitoring

Why Not Pharmacy Benefit:

  • IV-only administration requires clinical supervision
  • No oral formulation available
  • Complex dosing calculations based on patient weight
  • Monitoring for infusion reactions and renal function needed
Tip: Always verify with Cigna that your specific plan covers Amondys 45 under the medical benefit before initiating treatment. Some plans may have different pathways for specialty biologics.

ICD-10 Mapping for Duchenne Muscular Dystrophy

The primary diagnosis code for Amondys 45 coverage is G71.01 - Duchenne or Becker muscular dystrophy. This specific code was introduced to distinguish DMD from other muscular dystrophies, which is crucial for insurance reimbursement.

Documentation Requirements

Your clinical notes must include:

  • Confirmed DMD diagnosis with genetic testing results
  • Exon 45 mutation specifically documented
  • Current functional status (ambulatory vs. non-ambulatory)
  • Prior therapy trials and outcomes
  • Current weight for dosing calculations
  • Renal function baseline labs

Supporting Documentation Language

Use precise terminology in your notes:

  • "Duchenne muscular dystrophy confirmed by genetic testing"
  • "Mutation amenable to exon 45 skipping therapy"
  • "Patient remains ambulatory with [specify aids if applicable]"
  • "Previous corticosteroid therapy with [outcome]"
  • "Baseline creatinine [value] prior to casimersen initiation"

Product Coding: HCPCS, NDC, and Units Math

HCPCS J-Code: J1426

HCPCS J1426 covers "Injection, casimersen, 10 mg" - meaning each billing unit represents 10 mg of casimersen. This code became effective October 1, 2021.

NDC Numbers

The primary NDC for Amondys 45 is for the 100 mg/2 mL single-dose vial. Always verify the exact NDC format required by Cigna, as some payers require specific 11-digit formatting.

Dosing Calculations and Billing Units

Standard Dosing: 30 mg/kg IV once weekly

Step-by-Step Calculation:

  1. Patient dose (mg): Weight (kg) × 30 mg/kg = total mg dose
  2. Volume needed (mL): Total mg dose ÷ 50 mg/mL = mL to administer
  3. Vials required: mL needed ÷ 2 mL/vial = vials (round up, don't split vials)
  4. Billing units: Total mg dose ÷ 10 mg/unit = units for J1426

Example for 33.5 kg patient:

  • Dose: 33.5 kg × 30 mg/kg = 1,005 mg
  • Volume: 1,005 mg ÷ 50 mg/mL = 20.1 mL
  • Vials: 20.1 mL ÷ 2 mL/vial = 11 vials (rounded up)
  • Billing: 1,005 mg ÷ 10 mg/unit = 101 units (J1426 × 101)

Clean Prior Authorization Request Anatomy

A complete Cigna prior authorization for Amondys 45 includes these essential elements:

Patient Information Section

  • Member ID and demographics
  • ICD-10 code: G71.01
  • Current weight in kg
  • Prescriber NPI (must be neuromuscular specialist)

Clinical Justification

  • Genetic test results from CLIA-certified lab confirming exon 45 amenable mutation
  • Functional assessment documenting current ambulatory status
  • Prior therapies attempted (corticosteroids, other DMD treatments)
  • Baseline renal function (required for safety monitoring)

Dosing and Administration Plan

  • Calculated dose: 30 mg/kg = [specific mg amount]
  • Frequency: Once weekly IV infusion
  • Site of care: [Clinic/infusion center/home health]
  • Duration: Initial 6-month authorization request
  • Monitoring plan: Monthly weight checks, quarterly renal function

Billing Details

  • HCPCS code: J1426
  • Units per dose: [calculated units]
  • NDC: [verify current format with Cigna]
  • Expected monthly units: [weekly dose × 4.3]
Clinician Corner: Counterforce Health helps providers generate evidence-backed prior authorization requests by automatically pulling relevant clinical guidelines and structuring appeals according to each payer's specific requirements.

Frequent Coding Pitfalls

Unit Conversion Errors

Common mistake: Billing for total mg dose instead of 10 mg units

  • Wrong: Patient receives 1,000 mg → Bill J1426 × 1,000
  • Correct: Patient receives 1,000 mg → Bill J1426 × 100 (1,000 ÷ 10)

Mismatched Codes

Wrong HCPCS codes sometimes used:

  • J3590 (unclassified biologics) - Don't use for casimersen
  • J1427 - This doesn't exist for casimersen
  • Always use J1426 specifically

Missing Start Dates

Cigna requires the exact date of first infusion for tracking authorization periods and renewal timing. Missing or incorrect dates can delay approval.

Inadequate Genetic Documentation

Insufficient: "Patient has DMD" Required: "Genetic testing confirms DMD with deletion amenable to exon 45 skipping (attach lab report)"

Dosing Frequency Errors

Wrong: "As needed" or "monthly" Correct: "Once weekly" (every 7 days)

Verification with Cigna Resources

Before Submitting Your Request

  1. Check formulary status via Cigna's provider portal or call 1-800-882-4462
  2. Verify NDC format requirements for your specific Cigna plan
  3. Confirm prior authorization form - use current version from Cigna's website
  4. Review medical policy for Amondys 45 coverage criteria

Cigna-Specific Resources

  • Provider Portal: Direct submission with real-time status tracking
  • Prior Authorization Phone: 1-800-882-4462
  • Medical Policy: Cigna's casimersen coverage position
  • Specialty Pharmacy: Express Scripts/Accredo coordination

Cross-Check Your Codes

Verify these match Cigna's requirements:

  • HCPCS J1426 is covered for casimersen
  • NDC number format (11-digit vs. other)
  • ICD-10 G71.01 is accepted for DMD
  • Unit calculations align with 10 mg = 1 unit

Pre-Submission Audit Checklist

Clinical Documentation ✓

  • ICD-10 G71.01 documented in chart
  • Genetic test results attached showing exon 45 amenable mutation
  • Current weight documented for dosing
  • Functional status assessment completed
  • Prior therapy trials documented
  • Baseline renal function labs included

Coding Accuracy ✓

  • HCPCS J1426 used (not J3590 or other codes)
  • Billing units calculated correctly (mg dose ÷ 10)
  • NDC format verified with Cigna requirements
  • Dosing frequency specified as "once weekly"
  • Site of care clearly indicated

Administrative Details ✓

  • Current Cigna PA form used
  • Prescriber NPI included and verified
  • Member ID and demographics complete
  • Start date specified
  • Authorization duration requested (typically 6 months)

Appeals Process in Texas

If Cigna denies your initial prior authorization, Texas provides strong patient rights for appeals.

Internal Appeal (First Level)

  • Timeline: File within 180 days of denial
  • Decision time: 30 days for pre-service, 60 days post-service
  • Submit to: Address on patient's Cigna ID card
  • Required: Original denial, clinical records, physician letter

External Review (IRO)

After internal appeal denial, Texas allows Independent Review Organization review:

  • Timeline: File within 4 months of final Cigna denial
  • Decision time: 20 days standard, 5 days urgent
  • Process: Through Texas Department of Insurance
  • Binding: IRO decision forces Cigna compliance if overturned
Note: Counterforce Health specializes in turning insurance denials into successful appeals by identifying the specific denial basis and crafting targeted, evidence-backed rebuttals aligned to Cigna's own coverage policies.

Texas Resources

  • Texas Department of Insurance: 1-800-252-3439
  • IRO Information Line: 1-866-554-4926
  • Office of Public Insurance Counsel: 1-877-611-6742

FAQ

How long does Cigna prior authorization take for Amondys 45 in Texas? Standard review takes 72 hours; expedited reviews take 24 hours for urgent medical situations with documented rapid clinical decline.

What if Amondys 45 is non-formulary on my Cigna plan? Request a formulary exception with medical necessity documentation. Cigna reviews these within 72 hours and may approve based on clinical justification.

Can I bill Amondys 45 under the pharmacy benefit? No. Amondys 45 requires IV administration and is always billed under the medical benefit using HCPCS J1426.

What genetic testing documentation does Cigna require? CLIA-certified laboratory results confirming DMD with a mutation amenable to exon 45 skipping. Generic "DMD diagnosis" is insufficient.

How do I calculate billing units for different patient weights? Divide the total mg dose by 10. For example: 40 kg patient = 1,200 mg dose = 120 billing units (J1426 × 120).

Does step therapy apply to Amondys 45 in Texas? Cigna may require documentation of prior corticosteroid therapy or other DMD treatments, but specific step therapy requirements vary by plan.

What if my patient is non-ambulatory? Cigna covers Amondys 45 for both ambulatory and non-ambulatory DMD patients with appropriate genetic mutations. Document current functional status clearly.

How often can I bill for Amondys 45? Once weekly (every 7 days). Monthly billing would be approximately 4.3 doses per month.

Sources & Further Reading

Disclaimer: This information is for educational purposes and does not constitute medical advice. Coverage decisions vary by individual plan and clinical circumstances. Always verify current coding requirements and coverage policies directly with Cigna and consult with qualified healthcare professionals for patient-specific guidance. For additional support with complex prior authorizations and appeals, consider working with specialized services like Counterforce Health that focus on evidence-based insurance advocacy for specialty medications.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.